In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases. In another aspect, the present disclosure provides glutamine-containing substrates (or Q-tag substrates) that are more resistant to proteases/clipping and therefore, more stable, than other Q-tag substrates, and their uses in substrate tags for cross-linking to an amine-donor tag via an isopeptide bond mediated by a microbial transglutaminase.

The present invention relates to a method of prognosis and/or diagnosis of a pellicular condition of the scalp, based on the measurement of the quantity of the active form of transglutaminase 3. The present invention also relates to a cosmetic treatment method for the scalp, a method for identifying compounds for reducing and/or eliminating the pellicular condition. Finally, the present invention relates to a kit and the use thereof for identifying a compound for reducing and/or eliminating the pellicular condition.

The present invention relates to a method of enriching or screening for one or more target molecules from a primary source, which method comprises to provide at least one peptidic ligand comprising at least one lysine (K) and immobilized to a solid support; contacting the ligand(s) with a primary source comprising at least one target molecule comprising glutamine (Q); allowing the formation of complexes between the ligand and the target molecule; and separating the complexes from the primary source. The target molecule(s) comprises glutamine, and step c is performed in the presence of a catalytic protein comprising transglutaminase (TG). The catalytic protein comprising transglutaminase (TG) may comprise transglutaminase originating from fish, such as Atlantic cod TG (AcTG), e.g. AcTG-1, and the primary source may include waste material from the fish or dairy industry.

Combinations of the novel biological markers that can be used in the diagnosis of endometriosis are provided. The objective of the invention is to detect biological markers that are expressed differently in eMSCs isolated from endometrial biopsy samples in the diagnosis of endometriosis compared to healthy eMSCs. A tissue transglutaminase is configured as a biomarker for a diagnosis of an endometriosis in isolated endometrial mesenchymal stem cells derived from an endometrial biopsy and/or a menstrual blood from endometriosis patients.

The present invention relates to the technical field of thrombosis and hemostasis-related disease detection technologies, and in particular to a biomarker and an application thereof in thrombotic and coagulation-related disorders detection. The biomarker comprises an activated peptide of Coagulation Factor XIII (FXIIIAP) and/or an A subunit of Coagulation Factor XIII (FXIIIA). The diagnostic kit provided by the present invention comprises a capture antibody and a detection antibody, which is a specific antibody prepared by using FXIIIAP as an antigen. The biomarker of the present invention has a promising application prospect of rapid screening and diagnosis of thrombotic and coagulation-related diseases, including strokes, can significantly improve the sensitivity and specificity of existing diagnostic methods, speculate the thrombus formation timing and extent, and can predict the severity and prognosis of the disease.

Disclosed are a pharmaceutical composition and a method for preventing or treating diabetic complications caused by vascular leakage, comprising a TGase2 inhibitor, and a method of screening a preventive or therapeutic agent for diabetic complications caused by vascular leakage.

In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases.

A diagnostic method for determining prognosis of a myocardial infarcted patient, wherein the amounts of FXIII protein are determined on the day of myocardial infarction (t0) and at least on the following three days (t1 to t3), wherein a lowering of FXIII amount on any one of t0 to t3 below a threshold value is indicative of an increased risk of poor prognosis.

Methods are provided herein for vaccine development, characterization and validation. Using the response signatures disclosed herein, methods are provided for optimization, selection and benchmarking of vaccines, including adjuvants for vaccines. The methods include a prediction of response durability. e.g. the longevity of an antibody response, for a candidate vaccine or vaccine adjuvant; and assessment of similarity to a benchmark reference vaccine.

The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient comprising: (i) determining the number of alleles of ApoE4 in the patient's genome; (ii) determining the combined expression level of at least three platelet proteins in a platelet sample from the patient; and (iii) comparing the resulting value of step (ii) to a control value, wherein the at least three platelet proteins include at least one isoform of alpha-tropomyosin containing exon 1a and at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 or mutant GSTO-1, wherein a result higher than the control value is indicative of Alzheimer's disease. The invention also provides a solid support comprising one or more ligands of at least one isoform of alpha-tropomyosin containing exon 1a, and one or more ligands of at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 protein and/or mutant GSTO-1 protein immobilized thereon.